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Summary 
To evaluate the potential for dimerization through a particular T  cell receptor (TCR)  domain, 
we have cloned the cDNA encoding a TCR  Vo~ from a hybridoma with specificity for the hu- 
man  immunodeficiency  virus  (HIV)  envelope  glycoprotein  120-derived  peptide  P18-I10 
(RGPGRAFVTI)  bound to the murine major histocompatibility complex (MHC)  class I mol- 
ecule,  H-2D d. This cDNA was then  expressed in a bacterial vector,  and protein,  as inclusion 
bodies, was solubilized,  refolded,  and purified to homogeneity.  Yield of the refolded material 
was from 10 to 50 nag per liter of bacterial culture,  the protein was soluble at concentrations  as 
high as 25 mg/ml, and it retained a high level of reactivity with an anti-Vot2 monoclonal anti- 
body. This domain was monomeric both by size exclusion gel chromatography and by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis. Circular dichroism spectra indicated that the 
folded Vot domain had secondary structure  similar to that of single imrnunoglobulin  or TCR 
domains, consisting largely of [~ sheet. Conditions for crystallization were established, and at least 
two  crystal geometries were observed:  hexagonal b!pyramids that failed to diffract beyond ~6 
A, and orthorhombic  crystals that diffracted to 2.5 A. The dimerization  of the Vot domain was 
investigated further by solution nuclear magnetic resonance spectroscopy, which indicated that 
dimeric and monomeric forms of the protein were about equally populated at a concentration 
of I  raM.  Thus,  models  of TCR-mediated  T  cell  activation  that  invoke  TCR  dimerization 
must consider that some V~x domains have little tendency to form hornodimers or multimers. 
T 
he  TCR  is  a  heterodimeric  cell  surface  glycoprotein 
consisting of disulfide-linked  ci and [3 chains expressed 
clonally  on mature  T  lymphocytes bearing  the  coreceptor 
molecules  CD4  or CD8  (1).  These molecules bind a non- 
covalent complex consisting of an antigenic  or self peptide 
and an MHC-encoded  class I or class II molecule expressed 
on  the  surface  of APC  (2).  Activation  of CD8  or  CD4- 
expressing  T  lymphocytes  is controlled  by the  interaction 
of the  TCR  with  the  MHC-peptide  complex,  and  this 
molecular  interaction  plays  a  critical  role  in  the  initiation 
and perpetuation  ofT  lymphocyte responses to foreign an- 
tigens  or  to  dysregulated  self antigens,  such  as  those  ex- 
pressed  by  tumor  ceils  (3,  4).  The  discrimination  that  a 
TCR  makes in identifying an MHC  molecule or antigenic 
peptide  is exquisite.  Single-amino  acid substitutions  in  ei- 
ther the MHC  or the peptide ligand can eliminate or dras- 
tically diminish the cellular response mediated by a specific 
TCR  (5). Despite an ever-expanding battery of amino acid 
sequence  data  generated  from the  cloning and  sequencing 
of TCR  cDNAs and genes,  our understanding  of the rela- 
tionship of the structure of TCR  to the binding and cellu- 
lar signaling activity of these molecules is rudimentary.  The 
three-dimensional  x-ray  crystallographic  structures  of an 
MHC  class  II ligand  for  a  TCR,  human  HLA-DR1  (6), 
complexed with a peptide from influenza virus hemaggluti- 
nin  (7),  that of MHC  class  II complexed with a superanti- 
gen (8),  and that of a complex of the MHC  class II molecule 
HLA-DR3 complexed with the class II-associated invariant 
chain peptide  (CLIP) 1 fragment of the  invariant  chain  (9), 
all consistently show a dimer ofdimers. These observations 
provide the basis for a model in which the formation ofsu- 
perdimers of the MHC-peptide  complexes on cell surfaces 
plays a critical role in the ability to activate the T  ceil (6, 1{3). 
fAbbreviations used in this paper: CD, circular dichroism; CLIP, class II as- 
sociated invariant chain peptide; IPTG, isopropyl ~-D-thiogalactoside; 
NMR, nuclear magnetic resonance; RU,  resonance unit; SPR,  surface 
plasmon resonance. 
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structure  of a  TCR-]8  chain  derived from  an  MHC  class 
II-restricted, influenza virus-specific T  cell hybridoma was 
reported,  demonstrating  the  similarity of the  TCR  basic 
fold to that of the immunoglobulins  (11).  In addition, the 
three-dimensional structure  of a  single Vc~4.2  domain de- 
rived from  a  TCR  with  specificity for  the  mouse  MHC 
class II molecule I-A  u complexed with a myelin basic pro- 
tein-derived peptide has been  described (12).  In solution, 
this particular Vcx domain forms homodimers as assessed by 
their behavior in gel filtration chromatography (13), and in 
the crystal, it forms an Fv-like dimer, and the homodimers 
form  tetramers  through  crystal contacts.  This  tendency of 
the VoL4.2 to form superdimers led to a modification of the 
MHC-based model in that it supported a critical role of the 
o~ chain in the TCR  dimerization needed for signaling (12). 
As part of a continuing effort to understand the relation- 
ship of structure to function of TCR,  their interaction with 
MHC-peptide  complexes, and  the potential role of TCR 
dimerization in initiation of signaling events, we have be- 
gun to clone and express domains and combining sites from 
TCR  restricted to particular MHC-peptide  complexes. In 
this  article we  report  the  cloning of a  cDNA  encoding a 
Va domain from a T  cell hybridoma that is activated by the 
HIV-IIIB  envelope  glycoprotein  120-derived  peptide, 
P18-I10  (RGPGRAFVTI),  complexed  to  the  mouse 
MHC  I molecule, H-2D d. This domain has been expressed 
efficiently as inclusion bodies in Escberichia  a}li, and the sol- 
ubilized protein has been  quantitatively refolded, purified, 
and  characterized  serologically and  by  circular  dichroism 
(CD).  Conditions for crystallization have been established, 
and  the  domain,  soluble at high concentration  in low-salt 
buffers, has been analyzed for dimerization by nuclear mag- 
netic resonance (NMR). 
Materials  and Methods 
Cloning qfRearranged TCR  Va Genes.  B4.2.3 (14), a T cell hy- 
bridoma with specificity for the HIV-IIIB envelope glycoprotein 
120 peptide P18-I 10 (RGPGRAFVTI in the single-letter amino 
acid code) presented in the context of the MHC class I molecule 
H-2D  a, was used as the source for the cloning of TCR cDNAs. 
Total cellular RNA was extracted from B4.2.3  with the RNAgents 
Total RNA Isolation System (Promega Corp., Madison, WI) fol- 
lowing the manufacturer's protocol, mRNA was then isolated by 
adsorption  onto  an  oligo(dT)-biotinylated probe  (PolyATtract 
mRNA Isolation  System;  Promega Corp.). TCR-Vcx region-spe- 
cific cDNA was synthesized and cloned as described (15). Briefly, 
cDNA synthesis by reverse transcriptase (RT-MLV; GIBCO BRL, 
Gaithersburg, MD) was primed with specific synthetic oligonu- 
cleotides complementary to  oL chain  constant  region sequences 
upstream of the respective J-C junction. After second-strand syn- 
thesis, synthetic linkers were added to the 5' end and inserts were 
amplified by PCR  and  cloned into  the  BlueScript KS  + vector 
(Stratagene Inc., La Jolla, CA). DNA sequence of all inserts was 
determined  by  the  dideoxy  method  using  Sequenase  (United 
States  Biochemical Corp.,  Cleveland,  OH).  The  Vot  sequence 
was  compared with sequences in  GenBank using BLASTn (16) 
and showed a perfect match from the 5'  flanking region to the 
end of Vet with the sequence previously reported as Vex 2.6 (17, 
18). TheJ region was from Jot38 (19). 
Expression and In  Vitro Re  folding of Vol]ee Protein.  The  B4.2.3 
Vcr  domain construct was prepared by PCR amplification of the 
cloned ~  chain cDNA. The  primers used to generate Vet short 
and  VR  long  were  5'-GGAATTCCATATGGTGAGTGGC- 
CAGCAGGAG-3' (5' LONG OLIGO), 5'-GGAATTCCATA- 
TGCAGCAGGTGAGACAAAGTCC-3' (5'  SHORT  OLIGO), 
and  5'-CGCGGATCCTCATGGATTTACTACCAGACTTGT- 
CCC-3'  (3'  OLIGO).  PCR  was  carried  out  with  deep-vent 
polymerase (New England Biolabs, Beverly, MA) through 3{) cy- 
cles  of denaturation  at  94~  for  I  inin,  annealing at  50~  for 
2 min, and extension at 72~  for 3 min. PCR products were iso- 
lated by agarose gel electrophoresis and purified using QIAEX 
(Qiagen,  Inc., Chatsworth, CA). The PCR products were cleaved 
with the relevant restriction enzymes and cloned into the pET-3a 
vector (Novagen Inc., Madison, WI [20]).  The  integrity of the 
cloned fragment was verified by nucleotide sequence deternfina- 
tion. The Vix2.6J38 sequence reported here has been deposited in 
GenBank (accession number U63546). 
E.  coli strain BL21(DE3)  cells were  transformed with  pET3a 
constructs  containing  the  TCR-V&  domain  gene,  and  were 
grown in 5(10 ml to midlogarithmic phase (OD,{,{, =  0.6-{}.8) in 
Luria-Bertani (LB) broth containing carbenicillin (200  Ixg/ml) at 
37~  TCR-Vcx domain production was induced by addition of 
0.5 mM  isopropyl ~-D-thiogalactoside (IPTG). After incubation 
for 3 h, the cells were centrifuged, washed with TE buffer (10{I 
mM Tris, 2 mM EDTA, pH 8.0),  and resuspended in 2{) ml of 
TE containing hen egg lysozyme (0.25  mg/ml). After incubation 
at 4~  overnight, cell lysis was completed by sonication in  the 
presence of 0.1%  (wt/vol) sodium deoxycholate (DOC).  Deter- 
gent-insoluble inclusion bodies were pelleted in a rotor (model 
SS-34; Sorvall, DuPont Instruments, Wilmington, DE) at 15,00{) 
rpm  for  30  nfin,  washed  twice  in  TE  buffer  containing {I.l% 
DOC, and washed again with TE buffer lacking DOC three times. 
The  B4.2.3  TCR-Vot  domain  was  refolded  from  inclusion 
bodies  using  a  modification of published procedures  (21,  22). 
Briefly, the partially purified inclusion bodies were dissolved in 10 
nil of 6 M guanidinium hydrochloride, {),3 M  dithiothreitol, 2 mM 
EDTA, and 0.1  M  Tris, pH 8. After incubation at room temper- 
ature for  1-2  h,  protein was dialyzed against 6  M  guanidinium 
hydrochloride (pH 2)  at 4~  Mixed disulfide bonds were pro- 
duced by adding an equal volume of 6  M  guanidinium hydro- 
chloride, 0.4 mM oxidized glutathione, 4 mM EDTA, and 0.2 M 
Tris, pH 8, to the denatured protein in solution. After incubation 
at room temperature for 4 h, the solution was dialyzed against 6 M 
guanidine hydrochloride, 0. l M Tris, and 2 mM EDTA, pH 8, at 
4~  The protein was then diluted 1:1(10 into 0.4 M arginine, 0.4 
mM reduced glutathione, 2 mM EDTA, and 0.1  M  Tris, pH 8. 
After incubation at 6-I0~  with stirring for 4  d,  the renatured 
protein was extensively dialyzed against 20 mM glycine, pH 9. In 
some cases, the Vo~ domain was refolded by a modification of the 
method ofKurucz et al. (23). Inclusion bodies were solubilized in 
2% sodium lauryl sarcosinate (SLS),  50  mM  Tris HC1,  pH  8.0, 
and oxidized by addition of 50 fxM CuSO  4. This was made 6 M 
in urea, and SLS was removed on Dowex 1 (AG 1-X8; Bio-Rad 
Laboratories, Hercules, CA). Protein was then diluted 1:100 into 
0.4 M  arginine, 0.1  M  Tris, pH 8, and 2 mM  EDTA. This was 
then dialyzed against glycine as described above. Protein refolded 
by either protocol was then partially purified and concentrated by 
ion-exchange chromatography on a HiTrap Q  column (Pharma- 
cia LKB Biotechnology Inc., Piscataway, NJ)  equilibrated in 2(1 
mM glycine, pH 9,  and step eluted with PBS.  Further purifica- 
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dex  75L  column  (Pharmacia Biotechnology Inc.)  and  isocratic 
elution in PBS. The homogeneous peak was collected and con- 
centrated by centrifugal ultrafiltration with Centricon 3 (Amicon, 
Inc., Beverly, MA) membranes. The yield of purified protein var- 
ied between  10 and 50 mg from 1 liter of bacterial culture. Vci 
proteins refolded by either protocol were identical as assessed by 
SDS-PAGE,  gel chromatography, antibody reactivity, and  CD 
spectra. Crystals were obtained under the same conditions with 
material refolded either way. 
Real-Time Surface Plasmon Resonance.  Binding  of TCR.  pro- 
teins to  antibodies was evaluated by surface  plasmon resonance 
using a Pharmacia BIAcore  TM (Pharmacia Biosensor AB, Uppsala, 
Sweden).  All  binding  experiments  were  performed  at  25~ 
mAbs and TCR. domains were coupled through amino groups by 
conventional methods as previously described at pH 4.5-5.5 (24, 
25). TCR domains and mAbs were diluted into HBST (20 mM 
Hepes,  pH  7.1,  150  mM  NaCI,  3.4  mM  EDTA,  and  0.005% 
Tween 20)  and injected over either antibody or TCR. domain- 
coupled biosensor surfaces,  as described in detail elsewhere (26). 
The surfaces were regenerated by exposure to 50 mM phosphoric 
acid.  Rat  anti-mouse V0~2 mAb  (clone B20.1  [27])  and  anti- 
mouse VI37 (clone TP,310  [28]) were purchased from PharMin- 
gen (San Diego, CA). 
Analysis of Kinetics Binding Data.  Text  files  of data  gathered 
from experiments were imported into IGOR. Pro (WaveMetrics, 
Lake Oswego, Oregon) running on a Macintosh computer, and 
the binding curves (sensorgrams)  were fit to single and in some 
cases double exponential expressions (O'Shannessy et al.,  1993). 
R.ate constants for dissociation kinetics were determined based on 
sensorgrams collected from washout experiments performed at a 
flow rate of 100  txl/min, a rate shown to minimize the effects of 
rebinding. Curve fitting was performed using a single exponential 
function descriptive of one kinetic class of the dissociating com- 
plexes: Bt  =  B0 exp(-kotrt), where  Bt is binding at time t,  B, is 
binding at time 0,  and kotr is the apparent dissociation rate con- 
stant. For the determination of the association rate constants, the 
time scale was adjusted to zero at the beginning of the injection 
of the fluid phase analyte, and the association phase of the sen- 
sogram was fit to the exponential function: B  t =  Bn~ (1-exp(kobst)), 
where  B,.  is  the  maximal level of binding  in  resonance  units 
(RU), and kob~ =  (ko.c) +  kojr. c is the molar concentration of in- 
jected analyte, and ko,, is the apparent association rate constant in 
units of M-l s-~. Sensorgrams in the association phase were col- 
lected over a range of c, and kon was determined from the linear 
plot ofc versus kob  s. 
CD.  CD  spectra  were  measured  in  a  spectropolarimeter 
(modelJ500C;Jasco Inc., Easton, MD) equipped with a DP500N 
data processor at 25~  Protein concentrations were 100 btg/ml in 
a l-ram pathlength quartz cuvette. Data were digitized and down- 
loaded for curve fitting as described before (29). Spectra were an- 
alyzed in terms of secondary structure using CONTIN (30). 
Crystallization.  Screening  for  crystallization conditions  was 
perfomled in hanging drops using the sparse matrix screen of  Jan- 
carik and Kim (31) as implemented in Crystal Screen (Hampton 
R.esearch,  R.iverside,  CA).  The  most  reproducible  conditions 
were with 85-90'% 4.0 M Na formate, pH 7. 
Nuclear Magnetic Resonance Spectroscopy.  The  1H  NMR.  spec- 
tra  of solutions of Vot  short  protein  at  concentrations  ranging 
from 0.25 to 1.0 mM in PBS were recorded at 600 MHz, 25~ 
The transverse relaxation rates for backbone amides in well-struc- 
tured regions of a protein are relatively uniform, and values mea- 
sured for the overlapping amides in the 9.3-9.5-ppm region were 
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Figure  1.  Structure  of Vex long and Vcr  short  expression vectors.  A 
schematic of the pET3a  subclones of Vix  short and V~x long is shown. 
Partial amino acid sequences emphasizing the NH2 termini, the N  regions 
of the encoded proteins, and the J segments are shown. 
used to determine the rotational correlation time, "re, of the pro- 
tein. The empirical relation %  =  10-v/(5  ￿  "G) s  2 was used for 
calculating "r  c from the transverse relaxation time, T  2 (32). 
Results 
Cloning and Expression of TCR- Vol Domain.  The  nucleo- 
tide  sequence  of the  cDNA  encoding  the  Vo~  domain  of 
the  B4.2.3  hybridoma  indicated  that  the  hybridoma  ex- 
pressed Vo~2.6Jot38  with the junctional sequence shown in 
Fig.  1.  To  confirm  that  this  sequence  represented  that 
which was used by the B4.2.3  hybridoma, the hybridoma 
cells were  examined by surface immunofluorescence using 
VoL2-specific mAb  B20.1,  confirming  that  they  express  a 
receptor  of this  Vot  family  (data  not  shown).  Because  of 
ambiguity in the location of the codon encoding the NH 2- 
terminal amino  acid residue  of the  mature  Vot  chain  (17, 
18),  we  engineered  two  different  methionine  initiation 
codons (ATG) in the positions indicated in Fig.  1,  and the 
resulting proteins have been referred to as Vix long and Vci 
short.  A  single-chain  three-domain  TCR  with  specific 
binding and biological activity uses the Vor  short NH2-ter- 
minal sequence, suggesting that this is the natural length of 
the molecule (Plaksin, D., P. McPhie, and D.H. Margulies, 
manuscript in preparation). 
Both Vo~ long and Vix short proteins were  expressed at 
high  levels  (--40  txg/ml bacterial culture)  after IPTG  in- 
duction of bacteria containing the indicated plasmids (Fig. 
2  A).  To  obtain natively folded protein,  inclusion bodies 
were  either solubilized in guanidinium hydrochloride and 
refolded by  controlled reoxidation of disulfide bonds  and 
renaturation or solubilized in detergent,  oxidized, and re- 
folded as detailed in Materials and Methods. After concen- 
tration and partial purification by ion exchange chromatog- 
raphy,  concentrated  protein  was  further  purified  by  size 
exclusion  chromatography  on  a  Superdex  75L  (Pharmacia 
Biotech, Piscataway, NJ) column (Fig. 2  /3). As can be seen 
in  the  chromatogram,  even  at  this  stage  of purification, 
there was no convincing indication of a noncovalent dimer 
of the Vor  domain, although a rare chromatogram  (such as 
that shown)  revealed a suggestion of a dimer at a level in- 
sufficient for quantitation. When purified protein was con- 
centrated further by ultrafiltration to levels as high as 2 mM 
and  analyzed  again  on  either  Superdex  75L  or  Superdex 
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folded  Va  domains.  (A)  SDS- 
PAGE  of purified  Vex2 domains. 
Both Va long and Vex short  were 
expressed in E. coli as described m 
Materials  and  Methods,  and  pro- 
tein  was  refolded  and  purified 
through  both  ion  exchange  and 
size  exclusion  chromatographic 
steps as  described.  The  TCR do- 
mains were examined  after reduc- 
tion  of  disulfide  bonds  in  2(1% 
polyacrylamide  gel  containing 
SDS. The  molecular  size markers 
are  indicated  in  kilodaltons.  (B) 
Size  exclusion  chromatography 
under  native  conditions.  Samples 
of the  refolded  Va  domains  were 
analyzed by size exclusion chroma- 
tobn'aphy in PBS on Superdex  75L 
at a flow rate of 0.5 ml/min. Posi- 
tions  of molecular  size standards 
are indicated in kilodaltons. Absor- 
bance at 280 nm is plotted  in arbi- 
trary units. 
200L  columns  in  PBS,  no  indication  of a  dimer  was  ob- 
served. 
Circular  Dichroism  Reveals  Secondary  Structure  Similar  to 
That ofIg  VDomains.  To  evaluate  the  nature  of the  sec- 
ondary structure  of the refolded Vet domains,  protein puri- 
fied through both ion exchange and size exclusion chroma- 
tography  steps  was  examined by CD  spectroscopy  (Fig.  3). 
Spectra of both Vcx long and  Vet short showed characteris- 
tic  minima  at  215  nm  consistent  with  a  largely  13  sheet 
structure,  Spectra  were  analyzed  in  terms  of  secondary 
structure  using the  CONTIN  program  (30).  The  Vet long 
showed  41  +  10%  13  sheet  and  4  +  5%  et  helix;  the  Vet 
short  had  38  +  9%  13  sheet  and  5  +  5%  et  helix.  These 
spectra  are similar to those reported  for a  Vet4.2  TCR  do- 
main  (33)  and  to those  described  for single-chain  Fv TCR 
(34,  35).  These  all  have  similarities  to  the  spectra  of Ig V 
4 
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I  I  I  i  I  I 
200  220  240 
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Figure 3.  CD spectra of refolded Vc~ domains.  CD spectra were col- 
lected as described in Materials and Methods  at 25~  Spectra of Vex long 
and Vc~ short are indicated. 
domains  and Fab fragments  (36-40). 
Reactivity  with  l/a2-specific  mAb.  To  confirm that  the  re- 
folded protein  was  in  a  native  state,  we  analyzed  the  anti- 
body  reactivity  to  the  isolated  Vex2.6  domains  by  surface 
plasmon  resonance  (SPR).  The  specific mAb  B20.1  (anti- 
Vet2)  was  covalently  linked  to  the  dextran-modified  gold 
surface of an SPR biosensor chip, and the domains  (Vo~ short 
and  long,  respectively)  were  injected  in  solution  (Fig.  4). 
Binding  of the  purified  Vot long and  Vet short  proteins  to 
the immobilized antibody was clearly observed as the steady, 
time dependent increase in RU.  The dissociation  rate con- 
stant  koc  r  was  obtained  by  curve  fitting  to  the  washout 
phase,  0.032  (-+  0.001)  s -1  (which  corresponds  to  a  tl/2  of 
21  s).  Association phase  data were collected over a range of 
600 
500 
f  i  i 
V(x long to anti-Vet2   4OO ,  % 
300  i-w2 
200 
1  oo  Vc~ long or short to anti-VI37  0.  ~ .j"  w  long or shon  ~, 
100 ~  150  200  250  300 
Time (sec) 
Figure  4.  Vc~2 domains  bind  to  anti-V~x2 but  not  anti-V[87 mAb. 
Anti-Vot2  or anti-V[87 mAb was  coupled  to  a biosensor  chip  (~8,000 
FLU of each were coupled)  as described  in  Materials and  Methods.  V~ 
long or Va short was injected over the two mAbs at a flow rate of 10 ~1/ 
rain, and binding was detected  by SPR. The upward-pointing  arrow in- 
dicates the mitiation  of the wash-on  (association) phase, and  the down- 
ward arrow indicates the initiation of the wash-out (dissociation) phase. 
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Figure 5.  Failure  to detect dimerization in SPR assay. (A) Vet short 
was immobilized on a biosensor surface (to level of ~3,000 RU) as de- 
scribed in Materials and Methods and exposed to either the Vet short do- 
main in solution or an anti-Vet2 mAb as indicated at a flow rate of 10 p,l/ 
rain. B shows a blank surface. The concentration of anti-Vet2 was 100 
riM, and the concentration of the solution phase Vet short domain was in- 
jected at a concentration of either 100 nM or 100 p~M. 
concentration,  and the concentration-dependent kob  S were 
obtained  by  curve  fitting  as  described  in  Materials  and 
Methods. These were plotted against concentration, fit to a 
linear regression (r =  0.999)  and yielded a kon of 2.37  ￿  106 
M-Is  -1.  (The kor obtained from the y intercept of the c ver- 
sus  kobs plot  also  was  equal  to  0.032  s-l).  The  calculated 
equilibrium  dissociation constant  was  Ka  =  1.35  ￿  10 -~ 
M. The Vot2 domains also did not bind to the control anti- 
V[37 mAb, as expected. The Vcl2 domain was also immo- 
bilized  to  the  surface,  and  the  specific  anti-Vet2  mAb 
bound  tightly, with  a  much  longer tl/2,  due  to  the  biva- 
lency of the reaction (see Fig. 5 A). 
Crystallization and Preliminary X-Ray Analysis.  We  screened 
for conditions that supported the crystallization of both Vci 
long and Vtx  short.  Using a  sparse matrix screen  (31),  we 
found that Vct long crystallized in both a hexagonal bipyra- 
mid form and in an orthorhombic form. The hexagonal bi- 
pyramids did not  diffract to  more  than  6  A,  whereas  the 
orthorhombic crystals diffracted to 2.5 A. Preliminary x-ray 
diffraction analysis suggests that  the  orthorhombic  crystals 
have unit cell parameters a =  56.1 A, b =  78.4 A, c =  89.1 A. 
Space group  P21212 ,  was  indicated by systematic absences 
in the principle zones.  The  Matthews  coefficient  VM  (41) 
was 8.1  A3/dalton. Assuming the partial specific volume of 
the protein in the crystal to be 0.74 cc/g (the average value 
for  most  globular  proteins),  there  are  probably  four  Voe 
molecules in the asymmetric unit and a solvent content of 
'~40%. 
Analysis of Dimerization.  Having established the purity, 
native configuration, and homogeneity of the V~ domains, 
we  asked  whether  we  could  detect  dimers  even  at  high 
concentration  using  techniques  potentially more  sensitive 
than  gel  filtration  chromatography.  Because  the  SPR 
method permits the detection of molecular interactions of 
K d as high as 10 .4 M  under some conditions, we immobi- 
lized the  Vc~  short  domain  to  a  biosensor chip,  and  then 
exposed the immobilized protein to  very high  concentra- 
tions  of the  V0~  domain  in  solution.  As  shown  in  Fig.  5, 
even  at concentrations as high as  100  IxM,  no  binding to 
the  immobilized Va  was  observed.  The  level of the  RU 
'  I  '  '  '  '  I  '  '  '  '  I  '  '  '  '  I  '  '  '  '  I  '  '  '  ' 
ppm  i0  9  8  7 
Figure 6.  ~H NMR spectrum of the amide region of Vtx short, re- 
corded from a 0.25-ram  solution at 600 mHz, 25~  The transverse re- 
laxation rates for backbone amide protons were used to determine the ro- 
tational correlation time, %, of the protein, as described in Materials and 
Methods. 
signal observed is due to the refractive index change due to 
the  high  concentration  of protein,  and  was  no  different 
when these same protein solutions were passed over a con- 
trol  surface  (Fig.  5  /3).  As  a  positive control,  a  very low 
concentration  (100  nM)  of the anti-Vot2 mAb bound  the 
immobilized Vot domain very well (Fig. 5 A). 
Finally, we have  examined the dimerization characteris- 
tics of the  Vot  short  domain  by solution  NMR  spectros- 
copy.  For  macromolecules,  the  transverse  relaxation rate 
(T  2-1) of the 1H resonances increases linearly with the rota- 
tional correlation time of the protein. The rotational corre- 
lation time is a direct function of the molecular size of the 
protein. Because the amide region of the  1H  NMR  spec- 
trum of V0t short is well behaved (see Fig. 6), we have used 
the  measured  values  of  T 2,  determined  as  a  function  of 
concentration,  to  assess the  dimerization. At a  concentra- 
tion of i  mM, the backbone amide protons of Vtx short re- 
lax relatively uniformly at a  rate  of 48  +  2  s -1.  This rate 
decreases to 36  -+ 2 s -1 at 0.5 mM, and 33  --- 2 s -1 at 0.25 
mM. A  relaxation rate of 33 s  -1 corresponds to a rotational 
correlation time of 6.6  +  0.6 ns (32), which is close to the 
value  expected  for  a  nearly  spherical globular protein  of 
N14  kD  at  25~  (Vot  short  has  a  calculated  molecular 
weight  of 12,688  daltons,  and  that  determined  by  SDS- 
PAGE  and  size exclusion gel chromatography is ~14  kD 
[see Fig. 2]). The increase in rotational correlation time ob- 
served at higher concentrations is indicative of a rapid ex- 
change between monomeric and dimeric forms of the pro- 
tein,  with  the  monomeric  and  dimefic  states  roughly 
equally populated at 1 mM.  Thus, the Ka for the dimeriza- 
tion  reaction,  2(Vci)  ,  "  (Vo{)2 ,  is  estimated to  be  1  + 
0.5 raM. 
Discussion 
We  report  here  the  biochemical,  serological, and  bio- 
physical properties ofa murine TCR  Vo~ domain expressed 
as inclusion bodies in E.  coli. Using minor modifications of 
standard refolding protocols, the inclusion bodies are easily 
solubilized,  and  the  single  intrachain  disulfide  bond  is 
readily formed. No covalent dimers or multimers were ob- 
served. Upon  removal of denaturant and transfer to native 
conditions, the protein exhibits a  CD  spectrum consistent 
with being a  single-Ig-like domain.  The  refolded domain 
1255  Plaksin et al. binds  to  the  single  available  Vc~2-specific  mAb,  and  this 
epitope is sensitive to thermal denaturation in native buffer 
(data  not  shown).  Thus,  in  addition  to  other  Ig domains 
that have been expressed as inclusion bodies in E.  coli (42), 
we  have  now  demonstrated  the  utility  of expressing  the 
TCR-V(x  domain  in  this  manner.  At  lower  yield,  some 
TCI< Fv constructs  have  also been  expressed  as  inclusion 
bodies (22, 34, 43).  This approach is similar to that used in 
the expression of antibody (44-47) and V0t (33) domains in 
E.  coli  using bacterial  leader  peptides  to  direct  the  newly 
synthesized protein to the periplasmic  space, but offers the 
advantage that  the preparation  of the  inclusion bodies is a 
simple  first  step  in  the  purification  of the  protein.  The 
yields we have achieved are  excellent  and  compare favor- 
ably with the maximum amounts that can be prepared from 
bacterial ceils  in systems that exploit the high-level expres- 
sion of a single mRNA  by virtue  of the use of the highly 
processive T7 RNA polymerase (20). The major disadvan- 
tage with intracellular expression as inclusion bodies is that 
the  insoluble  protein  must  be  solubilized  and  refolded; 
however,  at least  in the  case  of this  single-domain  TCR- 
Vot,  refolding  can  be  performed  efficiently.  This  domain 
crystallizes  readily,  an indication  of its  purity.  In addition, 
such  homogeneous  preparations  of  TC1K-Vo~  domains 
should  prove  invaluable  in  immunization  for family-  and 
subfamily-specific mAbs. 
The  ability to produce  such large amounts  of homoge- 
neous  and  soluble  TCR-Vix  domain  has  permitted  us  to 
examine  in  detail  the  nature  of the  dimerization  in  solu- 
tion. The Vo~ domain that we report here only dimerizes in 
solution  at  very  high  concentration,  with  a  dimerization 
constant estimated from IH NMP, spectroscopy of 1 mM. 
This weak dimerization is in marked contrast to that of the 
Vo~4.2 domain studied by Fields et al. (12,  13), which puri- 
fies as a 25-kD homodimer in solution. Two distinct types 
of Vot  dimerization  should be  considered:  one  that  forms 
the VH/VL-like Fv dimer through the largely hydrophobic 
interactions  of the  Vot domains  which may be  influenced 
by amino  acid  differences  in  different  V0~s; and  a  second 
that is the result of two V(x dimers to form (VodVc~)e  su- 
perdimers.  The  weak  dimerization  of the  V0t2.6  domain 
that  we  observe in  solution  is  presumably that  of the  first 
type, and  the  strong dimerization  noted by Fields  et al.  in 
solution is also likely to be similar. The model proposed by 
Fields et al.  (12) is that the structure of the TCR  promotes 
the formation of a cell surface (Vc~V13)2 tetramer as part of 
an early signal in T  cell activation.  Because the Vcr  do- 
main  they  studied  dimerizes  in  solution  (presumably 
through  the  VHVL-like  interface  observed  in  the  crystal), 
and because its crystals reveal a dimer ofdimers that contact 
through the C" strands of the Vcis,  these authors have sug- 
gested  that  the  dimerization  of the  complete  cell  surface 
TCR  is largely mediated  through Vet.  Structural  evidence 
consistent with this view is that the folding topology of the 
13 strands of the V(x4.2 domain pairs the C" strand with the 
D  strand,  an organization distinct from that of typical Ig V 
domains  in  which  the  C"  strand  hydrogen  bonds  to  C'. 
The  reorganization  of these  strands  in  the  Vix4.2  crystal 
structure  allows  the  packing  of the  Vo~  domains,  which 
would be  sterically  impeded  in  Ig V  domains  or V13. Al- 
though we cannot yet address the issue of crystal packing in 
the  Vot2.6 domain  we describe  here,  the fact that we  ob- 
served  no  dimer  at  reasonable  concentrations  in  solution 
and  required  concentrations  of at  least  0.5  mm  to  detect 
some by 1H NMR  suggests that not all  Vc~ domains  have 
the same tendency to form the VHVL-like dimer.  The issue 
of dimerization of molecules confined to the cell surface is 
more complex than that of molecules in solution, and weak 
molecular  interactions  as  measured  with  soluble  domains 
may  prove  significant  for  cell  surface  receptors  (48,  49). 
Thus, whether TCR  dimerization is mediated,  enabled,  or 
enhanced  by conserved  interactions  through  V(x  will  re- 
quire  additional  knowledge  of the  structure  of V(x2.6  as 
well as of complete TCP, and TCR-MHC-peptide  com- 
plexes.  Inspection of the amino acid sequence of the Vel2.6 
domain in the region of the C" and D  strands indicates that 
this Vo~ differs significantly from the Vix4.2  of Fields et al. 
(12).  Whether the Vo~2.6  domain  exhibits  the same strand 
pairing  as  Vet4.2  and  whether  its  decreased  ability  to 
dimerize  reflects  structural  differences  in  the  C"  and  D 
strands remain to be determined. The Vo~2.6 domain that we 
have  examined is derived from an MHC  class  I-restricted 
TCR,  whereas  the  Vo~4.2  domain  studied by Fields  et  al. 
(12) is from an MHC  II-restricted TCR.  It thus remains a 
formal  possibility  that  dimerization  potential  through  Vct 
reflects the MHC class specificity of the TCP,, though evi- 
dence suggesting a role of MHC  I dimers in T  cell activa- 
tion  (50)  and against MHC  I versus MHC  II bias of TCR 
repertoire  (5l) would argue against such an explanation. 
Thus,  our  characterization  of a  Vo~2.6  domain  derived 
from a TCR specific for an MHC class I (H-2Dd)-restricted, 
viral peptide-specific  (P,  GPGRAFVTI) complex raises  the 
possibility that TCR  dimerization through the Vo~ domain 
is not an obligate property of this domain, but, perhaps like 
the  dimerization  of Ig Vt.  domains  (45,  52,  53),  reflects 
unique  differences  between  particular  molecules.  Addi- 
tional structural and binding studies of cell membrane com- 
ponents involved in T  cell signaling should help clarify the 
contribution of the V(x domain. 
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